These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 970783)

  • 41. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Intravascular coagulation, thrombopenia, intracerebral hematoma attributable to heparin therapy].
    Derlon A; Derlon JM; Leporrier M; Letellier P; Dreyfus B; Clauvel JP; Piette JC; Vernant JP
    Nouv Rev Fr Hematol (1978); 1982; 24(6):383-7. PubMed ID: 7167388
    [No Abstract]   [Full Text] [Related]  

  • 43. Prothrombin utilization following addition of platelet confactor I concentrates to hemophilic plasma.
    JOHNSON JF; MAMMEN EF; SEEGERS WH
    Thromb Diath Haemorrh; 1959 Sep; 3():588-92. PubMed ID: 14407473
    [No Abstract]   [Full Text] [Related]  

  • 44. [Clinical use of factor IX concentrates].
    Nyman D
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1188-90. PubMed ID: 1215901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 46. [Thrombogenicity of a new prothrombin complex concentrate].
    Klöcking HP; Klessen C; Jablonowski C; Meerbach W; Dornheim G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1984; 111(5):645-61. PubMed ID: 6083940
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proceedings: Prothrombin-complex concentrates, thromboses, and factor VIII inhibitors: evidence for a coagulant formed by the interaction of factors X and II.
    Tishkoff GH
    Thromb Diath Haemorrh; 1975 Nov; 34(2):589. PubMed ID: 1198500
    [No Abstract]   [Full Text] [Related]  

  • 48. Mechanism of action of recombinant activated factor VII: an update.
    Hedner U
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Immunoallergic complication induced by rifampicin with disseminated intravascular coagulation].
    Denis J; Robert A; Johanet C; Homberg JC; Opolon P; Levy VG
    Presse Med; 1983 May; 12(23):1479-81. PubMed ID: 6222344
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Studies on the thrombogenic activities in two prothrombin complex concentrates.
    Hedner U; Nilsson IM; Bergentz SE
    Thromb Haemost; 1979 Oct; 42(3):1022-32. PubMed ID: 315624
    [No Abstract]   [Full Text] [Related]  

  • 51. Acute promyelocytic leukemia in a patient with hemophilia. Evidence for rapid consumption of clotting factors.
    Green D
    Thromb Diath Haemorrh; 1972 Jul; 27(3):516-22. PubMed ID: 4514294
    [No Abstract]   [Full Text] [Related]  

  • 52. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Chemical, clinical and immunological studies on the products of human plasma fractionation; the coagulation defect in hemophilia; the effect in vitro and in vivo on the coagulation time in hemophilia of a prothrombin and fibrinogen-free normal plasma and its derived protein fractions.
    LEWIS JH; SOULIER JP; TAYLOR FH
    J Clin Invest; 1946 Nov; 25(6):876-9. PubMed ID: 20282730
    [No Abstract]   [Full Text] [Related]  

  • 54. [Staphylocoagulase and staphylothrombin].
    Zajdel M; Wegrzynowicz Z; Sawecka J; Jeljaszewicz J
    Postepy Hig Med Dosw; 1977; 31(1):17-31. PubMed ID: 325544
    [No Abstract]   [Full Text] [Related]  

  • 55. Thromboembolic complications.
    Kasper CK
    Thromb Diath Haemorrh; 1975 Jun; 33(3):640-4. PubMed ID: 1154319
    [No Abstract]   [Full Text] [Related]  

  • 56. Use of factor-VII-rich prothrombin complex concentrate in liver disease.
    Green G; Dymock IW; Poller L; Thomson JM
    Lancet; 1975 Jun; 1(7920):1311-4. PubMed ID: 49516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endogenous thrombin potential as a novel method for the characterization of procoagulant snake venoms and the efficacy of antivenom.
    Isbister GK; Woods D; Alley S; O'Leary MA; Seldon M; Lincz LF
    Toxicon; 2010 Aug; 56(1):75-85. PubMed ID: 20338189
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improved coagulation in bleeding disorders by Non-Anticoagulant Sulfated Polysaccharides (NASP).
    Liu T; Scallan CD; Broze GJ; Patarroyo-White S; Pierce GF; Johnson KW
    Thromb Haemost; 2006 Jan; 95(1):68-76. PubMed ID: 16543964
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Significance of intravascular blood coagulation in the pathogenesis of pregnancy complications].
    Kiriushchenkov AP; Bokarev IN; Makatsariia AD
    Akush Ginekol (Mosk); 1977 Mar; (3):1-4. PubMed ID: 331983
    [No Abstract]   [Full Text] [Related]  

  • 60. Normotest--thrombotest discrepancy in congenital coagulation disorders of the prothrombin complex and in coumarin-treated patients: a nonspecific phenomenon.
    Girolami A; Brunetti A; Patrassi GM
    Am J Clin Pathol; 1977 Jan; 67(1):57-60. PubMed ID: 831455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.